Latest News
Aug 21, 2014
OxSonics Limited Nominated & Shortlisted For “Best New Medtech Development Programme” Award

Oxford, UK – 21 August 2014 – OxSonics Limited (“OxSonics”), a University of Oxford spin-out company developing a new generation of ultrasound-based medical devices, today announced it has been nominated and shortlisted as a finalist in the national OBN awards in the category of “Best New Medtech Development Programme”.

OxSonics was established in July 2013 to develop and commercialise a range of medical devices including “SonoTran”, an innovative drug delivery platform. SonoTran has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumour volumes including to those areas that lie farthest from blood vessels. Not only can SonoTran be applied to any oncological drug class, it also provides on-screen feedback to the clinician as to where and when successful drug delivery has taken place, maximising its therapeutic potential by ensuring complete tumour coverage.

The awards celebrate the key achievements within the bioscience and medical technology sector over the last year. OBN is a not-for-profit business network that provides comprehensive support for biotech and medtech companies in the Oxford and South-East biocluster and beyond.

Dr Colin Story, Chief Executive Officer of OxSonics commented: “We are delighted to not only have been nominated but also to have been shortlisted to one of just three companies in this prestigious award nomination category.”

 

- ENDS -

 

About OxSonics Limited

OxSonics was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics “SonoTran” drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics is based in Oxford, UK. For more information please visit: www.oxsonics.com.

 

About OBN

The OBN is the membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Our 360-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising and advocacy activities. For more information please visit: www.obn.org.uk.

   PDF Version
© OxSonics Ltd 2016